BRPI0712073A2 - cÉlulas produtoras de polipeptÍdio - Google Patents

cÉlulas produtoras de polipeptÍdio Download PDF

Info

Publication number
BRPI0712073A2
BRPI0712073A2 BRPI0712073-7A BRPI0712073A BRPI0712073A2 BR PI0712073 A2 BRPI0712073 A2 BR PI0712073A2 BR PI0712073 A BRPI0712073 A BR PI0712073A BR PI0712073 A2 BRPI0712073 A2 BR PI0712073A2
Authority
BR
Brazil
Prior art keywords
nucleic acid
producing cells
polypeptide
stop codon
splice
Prior art date
Application number
BRPI0712073-7A
Other languages
English (en)
Inventor
Endl Josef
Kopetzki Erhard
Ploettner Olivier
Schwarz Ursula
Tiefenthaler Georg
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of BRPI0712073A2 publication Critical patent/BRPI0712073A2/pt
Publication of BRPI0712073B1 publication Critical patent/BRPI0712073B1/pt
Publication of BRPI0712073B8 publication Critical patent/BRPI0712073B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

CÉLULAS PRODUTORAS DE POLIPEPTÍDIO. A presente invenção descreve um ácido nuclélco compreendendo, na direção 5' a 3': a) um primeiro ácido nucléico que codifica um polipeptídio heterólogo sem um códon de parada em fase de leitura, b) um segundo ácido nucléico começando com um sítio doador de splice 5' e terminado por um sítio receptor de splice 3' compreendendo um códon de parada de tradução em fase de leitura e um sinal de poliadenilação, e c) um ácido nucléico que codifica i) pelo menos um fragmento de um domínio transmembrana, ou ii) um peptídio de sinal para uma âncora GPI.
BRPI0712073A 2006-05-17 2007-05-15 ácido nucléico para produção de um polipeptídio ou proteína heteróloga BRPI0712073B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06010146 2006-05-17
EP06010146.6 2006-05-17
PCT/EP2007/004313 WO2007131774A1 (en) 2006-05-17 2007-05-15 Polypeptide producing cells

Publications (3)

Publication Number Publication Date
BRPI0712073A2 true BRPI0712073A2 (pt) 2012-03-06
BRPI0712073B1 BRPI0712073B1 (pt) 2019-11-12
BRPI0712073B8 BRPI0712073B8 (pt) 2021-05-25

Family

ID=37076089

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0712073A BRPI0712073B8 (pt) 2006-05-17 2007-05-15 ácido nucléico para produção de um polipeptídio ou proteína heteróloga

Country Status (12)

Country Link
US (2) US8354516B2 (pt)
EP (2) EP2027273B1 (pt)
JP (1) JP4870208B2 (pt)
KR (1) KR101202498B1 (pt)
CN (1) CN101410525B (pt)
AU (1) AU2007251766B2 (pt)
BR (1) BRPI0712073B8 (pt)
CA (1) CA2651478C (pt)
ES (2) ES2573027T3 (pt)
IL (1) IL193721A (pt)
MX (1) MX2008013514A (pt)
WO (1) WO2007131774A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2027273B1 (en) * 2006-05-17 2016-04-13 F. Hoffmann-La Roche AG Polypeptide producing cells
WO2008070367A2 (en) 2006-11-01 2008-06-12 Facet Biotech Corporation Mammalian cell-based immunoglobulin display libraries
US7947495B2 (en) 2007-11-01 2011-05-24 Abbott Biotherapeutics Corp. Immunoglobulin display vectors
AU2009286956B2 (en) 2008-08-28 2012-12-06 Novartis Ag Cell surface display of polypeptide isoforms by stop codon readthrough
JP5801207B2 (ja) 2009-02-27 2015-10-28 ノバルティス アーゲー ２種類の選択マーカーを含む発現ベクター系
FR2944016B1 (fr) 2009-04-02 2012-03-09 Isp Investments Inc Nouveaux peptides anti-age activateurs du proteasome et compositions les contenant
FR2944018B1 (fr) * 2009-04-02 2012-03-09 Isp Investments Inc Nouveaux peptides anti-age activateurs du proteasome et compositions les contenant
FR2944017B1 (fr) * 2009-04-02 2012-03-09 Isp Investments Inc Nouveaux peptides eclaircissants activateurs du proteasome et compositions les contenant
FR2944798B1 (fr) 2009-04-23 2013-05-10 Isp Investments Inc Hydrolysats peptidiques eclaircissants activateurs du proteasome et compositions les contenant
FR2944797B1 (fr) 2009-04-23 2013-05-10 Isp Investments Inc Hydrolysats peptidiques activateurs du proteasome et compositions les contenant
CN101875916B (zh) * 2009-11-27 2013-04-17 西安交通大学 一种fgfr1高表达的重组hek293细胞及其应用
MX359950B (es) 2012-11-20 2018-10-17 Novartis Ag Casete de expresión optimizado para expresar un polipéptido con un alto rendimiento.
WO2014126254A1 (ja) * 2013-02-18 2014-08-21 協和発酵キリン株式会社 膜結合型タンパク質発現ベクター
WO2014141037A1 (en) 2013-03-11 2014-09-18 Novartis Ag Method of screening cell clones
WO2014171826A1 (en) 2013-04-17 2014-10-23 Stichting Vu-Vumc Treatment of cognitive impairment in depressive disorders
RU2716977C2 (ru) 2013-07-31 2020-03-17 Новартис Аг Новые селективные векторы и способы селекции эукариотических клеток-хозяев
EP3083677B1 (en) 2013-12-20 2019-08-28 Novartis AG Novel eukaryotic cells and methods for recombinantly expressing a product of interest
JP6708548B2 (ja) 2013-12-20 2020-06-10 ノバルティス アーゲー 新規真核細胞および目的の生成物を組換え発現させるための方法
WO2015128509A1 (en) * 2014-02-28 2015-09-03 Glenmark Pharmaceuticals S.A. Expression constructs and methods for selecting host cells expressing polypeptides
US11623950B2 (en) 2015-07-09 2023-04-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Lentiviral vector expressing membrane-anchored or secreted antibody
GB2592821B (en) 2015-07-31 2022-01-12 Univ Minnesota Modified cells and methods of therapy
CN109790214B (zh) * 2016-09-29 2022-09-06 豪夫迈·罗氏有限公司 用于选择产生多肽的细胞的改进方法
CN110520530A (zh) 2016-10-18 2019-11-29 明尼苏达大学董事会 肿瘤浸润性淋巴细胞和治疗方法
EP3645021A4 (en) 2017-06-30 2021-04-21 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
WO2019015677A1 (en) * 2017-07-21 2019-01-24 Beijing Biocytogen Co., Ltd GENETICALLY MODIFIED IMMUNOGLOBULIN HEAVY CHAIN ANIMALS
CN107557367B (zh) * 2017-09-08 2020-11-03 北京大学人民医院 Ighg1基因突变体及其应用
WO2021168577A1 (en) * 2020-02-25 2021-09-02 Symvivo Corporation Gene delivery system
EP4256061A1 (en) * 2020-12-01 2023-10-11 ETH Zurich Dna constructs comprising alternative promoters
CN120865355A (zh) * 2024-04-29 2025-10-31 苏州系统医学研究所 一种工程化改造gpi锚定信号肽、其融合蛋白及应用
CN118420709B (zh) * 2024-04-29 2025-02-14 南京鼓楼医院 靶向cd73的肿瘤抗原肽、疫苗及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
IE913929A1 (en) 1990-11-13 1992-05-20 Immunex Corp Bifunctional selectable fusion genes
IL104570A0 (en) * 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
ES2257303T3 (es) 1999-07-12 2006-08-01 Genentech, Inc. Vectores de expresion y procedimientos.
AUPQ422399A0 (en) 1999-11-24 1999-12-16 University Of New South Wales, The Method of screening transformed or transfected cells
IL136459A0 (en) 2000-05-30 2001-06-14 Galim Galil Immunology Ltd Antibody library
US6919183B2 (en) 2001-01-16 2005-07-19 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
ATE311101T1 (de) 2001-07-30 2005-12-15 Smithkline Beecham Corp Abbildung von transgenen markern
US7384744B2 (en) 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
EP1477805A1 (de) 2003-05-12 2004-11-17 ProBioGen AG Verfahren zur Zellselektion
US9128090B2 (en) 2003-08-29 2015-09-08 Janssen Biotech, Inc. Rapid way to obtain high expression clones of mammalian cells using a methylcellulose and immunoprecipitation screening method
DE602004018349D1 (de) * 2003-10-16 2009-01-22 Claude Negrier MODIFIZIERTE cDNA FÜR HOHE EXPRESSIONSNIVEAUS VON FAKTOR VIII UND DESSEN DERIVATEN
CA2559280A1 (en) * 2004-03-15 2005-09-29 Biogen Idec Ma Inc. Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing
EP2027273B1 (en) * 2006-05-17 2016-04-13 F. Hoffmann-La Roche AG Polypeptide producing cells

Also Published As

Publication number Publication date
AU2007251766A1 (en) 2007-11-22
EP2027273B1 (en) 2016-04-13
CN101410525A (zh) 2009-04-15
BRPI0712073B1 (pt) 2019-11-12
US20130109058A1 (en) 2013-05-02
EP2208792A3 (en) 2010-10-27
IL193721A (en) 2014-09-30
MX2008013514A (es) 2008-10-28
US20090311725A1 (en) 2009-12-17
WO2007131774A1 (en) 2007-11-22
US8354516B2 (en) 2013-01-15
JP2009537124A (ja) 2009-10-29
CA2651478C (en) 2015-02-03
EP2027273A1 (en) 2009-02-25
EP2208792B1 (en) 2015-05-06
EP2208792A2 (en) 2010-07-21
US8541204B2 (en) 2013-09-24
KR20090003327A (ko) 2009-01-09
ES2573027T3 (es) 2016-06-03
IL193721A0 (en) 2011-08-01
ES2543629T3 (es) 2015-08-20
AU2007251766B2 (en) 2013-06-20
BRPI0712073B8 (pt) 2021-05-25
KR101202498B1 (ko) 2012-11-16
CA2651478A1 (en) 2007-11-22
JP4870208B2 (ja) 2012-02-08
CN101410525B (zh) 2012-09-05

Similar Documents

Publication Publication Date Title
BRPI0712073A2 (pt) cÉlulas produtoras de polipeptÍdio
BRPI0416544A (pt) proteìna de ligação de gag
CO6491059A2 (es) Diferenciacion de las celulas madre mesenquimales
BR112012007821A2 (pt) polipeptídeos para ligação ao "receptor de produtos finais de glicação avançada" bem como composições e métodos envolvendo os mesmos
BR112012008862A2 (pt) métodos para produzir uma glicoproteína recombinante e uma eritropoietina humana madura, e, composição
CL2009000284A1 (es) Antagonistas especificos de pro-proteina convertasa subtilisina-kexina tipo 9 humana (pcsk9), composicion farmaceutica que lo comprende; acidos nucleicos que lo codifican; vector, celula y proceso para producir dicho antagonista; util para mejorar un trastorno, afeccion o enfermedad inducida por pcsk9.
BRPI0911385B8 (pt) polipeptídeo isolado, polipeptídeo de fusão, multímero e composição farmacêutica
BR112014006509A2 (pt) fibras finas fabricadas a partir de polímero reticulado com composição de aldeído resinoso
AR067199A1 (es) Proteinas de union a antigenos que se unen a par-2
BR112012018163A2 (pt) métodos e composições para exibição de um polipeptídeo sobre a superfície de uma célula de levredura
BR112014020213A2 (pt) biomarcadores para o diagnóstico, o prognóstico, a avaliação e a estratificação de terapia de síncope
BR112013002062A2 (pt) peça combustível e processo de produção de uma peça de combustível
BRPI0921999B8 (pt) uso de uma quantidade terapeuticamente eficaz de células tronco placentárias
BRPI0611793A2 (pt) anÁlogos de epÍtopo
CO6270358A2 (es) Anticuerpos para gdf8 asi como sus usos
BR112012012160A2 (pt) material e métodos para tratar ou prevenir doenças associadas ao her-3
BRPI0817624A2 (pt) Conjunto de reforço para concreto e marcadores
BR112012028675A2 (pt) corda de viga compósita entre placas de reforço e método relacionado de fabricação
BR112012008665A2 (pt) tratamento de câncer
BRPI0607009A2 (pt) stent endoureteral absorvìvel composto reforçada com fibra
BR112013000928A2 (pt) sistema de fixação de trilho
CL2009000829A1 (es) Metodo para identificar un secretagogo del peptido yy (pyy) que comprende poner en contacto un compuesto de prueba con una celula huesped o con la membrana que contiene un receptor acoplado a proteina g de secuencia id no 2; determinar la capacidad estimular a este y la secresion de pyy en celula enteroendocrina de vertebrado.
BR112013002005A2 (pt) estrutura de segurança, documento de segurança e processo para autenticar um documento de segurança e uma da primeira e segunda composição da estrutura de segurança do documento formando pelo menos um padrão
CL2011000975A1 (es) Anticuerpo o fragmento del mismo que se une a al menos un residuo de animoacido del receptor tipo toll 3 (tlr3); composicion farmaceutica que lo comprende; su uso para tratar una condicion inflamatoria.
BR112013010918A2 (pt) sal de alumínio contendo elevada percentagem de al30

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/05/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2723 DE 14-03-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.